In the latest trading session, 3.48 million Alzamend Neuro Inc (NASDAQ:ALZN) shares changed hands as the company’s beta touched 0.19. With the company’s most recent per share price at $1.24 changed hands at -$0.45 or -26.62% at last look, the market valuation stands at $8.02M. ALZN’s current price is a discount, trading about -1496.77% off its 52-week high of $19.80. The share price had its 52-week low at $1.32, which suggests the last value was -6.45% down since then. When we look at Alzamend Neuro Inc’s average trading volume, we note the 10-day average is 33440.0 shares, with the 3-month average coming to 21.09K.

Analysts gave the Alzamend Neuro Inc (ALZN) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ALZN as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Alzamend Neuro Inc’s EPS for the current quarter is expected to be -$0.67.

Alzamend Neuro Inc (NASDAQ:ALZN) trade information

Instantly ALZN was in red as seen in intraday trades today. With action -8.82%, the performance over the past five days has been red. The drop to weekly highs of 1.9200 on Friday, 11/17/23 subtracted -26.62% to the stock’s daily price. The company’s shares are showing year-to-date downside of -85.36%, with the 5-day performance at -8.82% in the red. However, in the 30-day time frame, Alzamend Neuro Inc (NASDAQ:ALZN) is -58.89% down. Looking at the short shares, we see there were 47710.0 shares sold at short interest cover period of 2.11 days.

The consensus price target for the stock as assigned by Wall Street analysts is $56.25, meaning bulls need an upside of 97.8% from its recent market value. According to analyst projections, ALZN’s forecast low is $15.00 with $97.50 as the target high. To hit the forecast high, the stock’s price needs a -7762.9% plunge from its current level, while the stock would need to soar -1109.68% for it to hit the projected low.

Alzamend Neuro Inc (ALZN) estimates and forecasts

Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Alzamend Neuro Inc will fall -48.90%, while the growth in revenue is estimated to hit 25.60% for the next quarter.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -69.45%. The 2023 estimates are for Alzamend Neuro Inc earnings to decrease by -13.33%.

ALZN Dividends

Alzamend Neuro Inc is expected to release its next quarterly earnings report in December.

Alzamend Neuro Inc (NASDAQ:ALZN)’s Major holders

Vanguard Group Inc holds the second largest percentage of outstanding shares, with 0.14% or 0.14 million shares worth $0.17 million as of Sep 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Extended Market Index Fund and Vanguard Total Stock Market Index Fund. With 78546.0 shares estimated at $98182.0 under it, the former controlled 0.08% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 0.06% of the shares, roughly 57139.0 shares worth around $71423.0.